Eli Lilly posted the single most impressive earnings report of Feb 2-6 week, crushing Q4 estimates (revenue +43%, EPS +13% beat) and delivering guidance that exceeded Street expectations by +7% ($80-83B vs $77.6B for 2026).
Qualys (NASDAQ:QLYS – Get Free Report) had its price objective reduced by investment analysts at JPMorgan Chase & Co. from $117.00 to $113.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “underweight” rating on the software maker’s stock. JPMorgan Chase & Co.
Estee Lauder Companies (NYSE:EL – Get Free Report) had its price target decreased by investment analysts at JPMorgan Chase & Co. from $131.00 to $121.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s
Illumina (NASDAQ:ILMN – Get Free Report) had its price target lowered by JPMorgan Chase & Co. from $130.00 to $120.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the life sciences company’s stock. JPMorgan Chase &
Unum Group (NYSE:UNM – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $92.00 to $90.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the financial services provider’s stock.
